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EFFECTS OF BEVACIZUMAB, AN ANTI VASCULAR ENDOTHELIAL 
GROWTH FACTOR MONOCLONAL ANTIBODY, ON KIDNEY FUNCTION AND 
MORPHOLOGY  
SUMMARY 
Aim: To constitute an experimental rat model by using human VEGF monoclonal 
antibody bevacizumab, for observation of renal side effects of this treatment and to evaluate 
the effects of bevacizumab on rat kidney.  
Method: Thirtysix adult female Wistar albino rats has been divided as two main 
groups: “three days” and “21 days” . Each group has been divided in three; bevacizumab 10 
mg/kg and 20 mg/kg were administered intravenously from the tail veins of the two 
subgroups  and 1 mg/kg saline was administered to the third subgroup as control. Urine for 24 
hours for detection of proteinuria and blood samples for detection of renal funtions were 
collected before drug administration, third day of the drug administration and 21st day of the 
drug administration and rats were sacrified at third and 21st days for pathological examination 
of kidneys. 
Results: Twenty four hours urine protein excretion, creatinin excretion and urine 
protein/creatinin ratio were demonstrated as significantly increased on the third day of the rats 
administered 10 mg/kg bevacizumab; however, any significant increase of proteinuria 
couldn’t be shown on the 21 days group rats administered neither 10 mg/kg or 20 mg/kg. 
Pathological examination of rats sacrified on third day demonstrate the significant increase of 
bowman capsule gap and interstitial inflamation as correlated with the dosage of the drug. 
And the thickness of vessel wall as correlated with the dosage of drug was observed on the 
pathological examination of rats sacrified on 21st day.    
Conclusion: It has been shown that for constitution of an experimental rat model by 
using human VEGF monoclonal antibody bevacizumab, for observation of renal side effects 
of this treatment, bevacizumab administration of 10 mg/kg for three days is proper. 
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